 |
인쇄하기
취소
|
KFDA approves Avodart, BPH drug
GSK has received its approval in Korea for Avodart (dutasteride), the oral medicine for treating benign prostatic hyperplasia (BPH) in men.
Dutasteride inhibits 5-alpha-reductase, blocking the formation of the hormone dihydrotestosterone (DHT). DHT is produced from testosterone by 5-alpha-reductase. Biochemical analysis reveals higher level of DHT in the bloodstream of men with BPH and DHT ...
Dutasteride inhibits 5-alpha-reductase, blocking the formation of the hormone dihydrotestosterone (DHT). DHT is produced from testosterone by 5-alpha-reductase. Biochemical analysis reveals higher level of DHT in the bloodstream of men with BPH and DHT ...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.